SINOPHARM-CICC
Sinopharm-CICC is a private equity fund focused on investments in the healthcare industry under CICC Capital.
SINOPHARM-CICC
Status:
Active
Similar Organizations
C-Bridge Capital
Cambridge Capital is a private equity fund focused on investing in the health care industry.
StarCom Group
StarCom Group is a private equity group focused on investments in the consumer sector and high-tech companies.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-18 | Zhenge Biotech | Sinopharm-CICC investment in Series C - Zhenge Biotech | 100 M CNY |
| 2022-08-02 | Xingmai Technology | Sinopharm-CICC investment in Venture Round - Xingmai Technology | 100 M CNY |
| 2020-10-06 | Hinova Pharma | Sinopharm-CICC investment in Series C - Hinova Pharma | 1000 M CNY |
| 2020-08-05 | MicuRx Pharmaceuticals | Sinopharm-CICC investment in Series D - MicuRx Pharmaceuticals | 300 M CNY |
More informations about "Sinopharm-CICC"
Sinopharm CICC investment portfolio | PitchBook
Founded in 2016, Sinopharm CICC is a private equity investment fund management company based in Shanghai, China.See details»
ๅฝ่ฏไธญ้ Sinopharm-CICC Capital - LinkedIn
Sinopharm-CICC Capital was co-founded by Sinopharm and China International Capital Corporation (CICC) in October 2016. It focuses on investments in the healthcare industry.See details»
Sinopharm and CICC held a ceremony to sign a โฆ
Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, BeijingSee details»
Sinopharm CICC Portfolio Investments, Sinopharm CICC Funds, โฆ
About Sinopharm CICC Sinopharm CICC is a joint venture fund management company established by Sinopharm Capital and Sinopharm Holdings in 2016. The Sinopharm Zhongjin โฆSee details»
Sinopharm-CICC Capital | CompassList
Sinopharm-CICC Capital was co-founded by Sinopharm and China International Capital Corporation (CICC) in October 2016. It focuses on investments in the healthcare industry.See details»
Sinopharm successfully completed its H-share follow-on offering
Sinopharm Group Co. Ltd (โSinopharmโ) successfully completed its H-share follow-on offering on December 1st, 2014 (โThe Offeringโ). A total 198.8 million new H-shares were offered in this โฆSee details»
Sinopharm-cicc - BioCentury Company Profiles - BCIQ
Apr 7, 2020 Sinopharm-cicc - BioCentury Company Profiles for the biopharma industrySee details»
CICC Assisted Sinopharm Completing Its H-Share Follow-On โฆ
Apr 22, 2013 Sinopharm Group Co. Ltd successfully completed its H-share follow-on offering on April 10th, 2013 and raised HK$4.08 billion, or equivalently US$530 million. The Offering was โฆSee details»
Sinopharm-CICC - Investments, Portfolio & Company Exits
Jan 1, 2025 Sinopharm-CICC is a private equity fund focused on investments in the healthcare industry under CICC Capital.See details»
Sinopharm (company) - Wikipedia
Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: ไธญๅฝๅป่ฏ้ๅขๆปๅ ฌๅธ) on November 26, 1998, as a holding company for China National โฆSee details»
Group Introduction_Who are we_CHINA SINOPHARM โฆ
The Sinopharm COVID-19 vaccine has registered in 119 countries, regions, and international organizations, and the vaccination population covers 196 countries. 04 Strategic Leadership โฆSee details»
WHO team working with Chinese vaccine producers ahead of โฆ
Jan 13, 2021 The World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus has said that a WHO team in China is working with producers of the Sinovac โฆSee details»
Sinovac, Sinopharm show safety, efficacy: WHO
Apr 6, 2021 Chinese vaccine makers Sinopharm and Sinovac have presented data on their COVID-19 vaccines demonstrating safety and good efficacy against symptomatic COVID-19 โฆSee details»
Sinopharm-CICC - Updates, News, Events, Signals & Triggers
Jan 1, 2025 Sinopharm-CICC is a private equity fund focused on investments in the healthcare industry under CICC Capital.See details»
WHO approves China's Sinopharm vaccine for emergency use
The World Health Organization announced on May 7 it will give emergency use authorization to the COVID-19 vaccine manufactured by China's Sinopharm.See details»
ใCGTNใA sneak peek into China's Sinopharm vaccine โฆ
Feb 27, 2021 Sinopharm CNBG is capable of annually producing one billion doses of its COVID-19 vaccine, according to the Chinese pharmaceutical group that runs the site through its โฆSee details»
WHO Endorses Chinaโs Covid-19 Vaccine Sinopharm - WSJ
The World Health Organization approved Chinaโs Sinopharm Covid-19 vaccine for emergency use, saying it will improve access to shots in the developing world.See details»
Li Zhiming - Crunchbase Person Profile
Aug 5, 2020 CoinGeek โ How to achieve mass adoption: The Bitcoin Bridge talks to DotWallet founder Lin ZhemingLi Zhiming is a chairman of Sinopharm-CICC.See details»
Sinopharm-CICC - Crunchbase
Sinopharm-CICC is a private equity fund focused on investments in the healthcare industry under CICC Capital.See details»
China's Sinopharm COVID-19 vaccine safe, efficacious: WHO official
GENEVA -- China's Sinopharm COVID-19 vaccines, very much used globally, have been considered both safe and efficacious, according to Mariangela Simao, World Health โฆSee details»